Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04228744
Other study ID # 2019 NAc VIC DBS OCD
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 10, 2020
Est. completion date December 31, 2022

Study information

Verified date January 2020
Source Ruijin Hospital
Contact Chencheng Zhang, PhD
Phone +086-18217122884
Email i@cczhang.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the efficacy and explore the mechanism of deep brain stimulation (DBS) in the ventral internal capsule (VIC) and nucleus accumbens (NAc) for refractory obsessive-compulsive disorder (OCD).


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date December 31, 2022
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Diagnosis of OCD with duration of at least 5 years;

2. Severity rated as severe to extreme illness;

3. Failed adequate trial of at least three specific serotonin reuptake inhibitor (SSRI) antidepressants;

4. Failed augmentation with antipsychotic;

5. Completed or failed to complete adequate trial of cognitive behavioural therapy for OCD;

6. Stable medication regimen for one month before surgery;

7. Signed informed consent;

Exclusion Criteria:

1. Hoarding as a primary symptom;

2. No other serious psychiatric disorder such as psychotic disorder;

3. Drug or substance use disorder within 6 months except nicotine;

4. Major Neurological/Medical condition;

5. High suicide risk;

6. Pregnancy or lactation;

7. Contraindications to stereotactic surgery;

8. Contraindications to MRI;

Study Design


Related Conditions & MeSH terms


Intervention

Device:
DBS system
The DBS device utilized in the present study includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller. The lead contains four stimulating contacts. The length of each contact is 1.5 mm, and the spacing between contacts is 1.5 mm. The participants will receive stepwise surgery. The electrodes will be implanted firstly which will be externalized for several days and then the IPG will be implanted. During externalization, the experimenters will record the local field potential and electroencephalography in resting or task-based state with conditions of sham-stimulation or active-stimulation.

Locations

Country Name City State
China Ruijin Hospital Shanghai

Sponsors (2)

Lead Sponsor Collaborator
Ruijin Hospital University of Cambridge

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score Y-BOCS is used to rate the severity of OCD symptoms by clinicians. Higher score means more severe OCD symptoms. Baseline (preoperative), 1 month, 3 months, 6 months, 12 months, 18 months
Secondary Change in Yale-Brown Obsessive-Compulsive Scale-Self Report (Y-BOCS-SR) Score The Y-BOCS-SR is a self-report version of the clinician-rated Y-BOCS. It consists of 10 items rated on a 5-point Likert scale (0 to 4) with higher scores denoting greater symptom severity. Baseline (preoperative), 1 month, 3 months, 6 months, 12 months, 18 months
Secondary Change in Yale-Brown Obsessive-Compulsive Scale-Second Edition (Y-BOCS-II) Score The Y-BOCS-II was created given several overarching concerns about the original Y-BOCS. Each item is rated from 0 to 5, and higher score means more severe OCD symptoms. Baseline (preoperative), 1 month, 3 months, 6 months, 12 months, 18 months
Secondary Change in Obsessive-Compulsive Inventory - Revised (OCI-R) Score The OCI-R is an 18-item self-reported scale that assesses the degree of distress caused by OCD symptoms. Each item is rated from "not at all" (codes as 0) to "extremely" (codes as 4), and three items constitute a subtype of OCD symptoms. Baseline (preoperative), 1 month, 3 months, 6 months, 12 months, 18 months
Secondary Adverse Events Baseline (preoperative), 1 month, 3 months, 6 months, 12 months, 18 months
Secondary Changes in Hamilton Anxiety Scale Score The Hamilton Anxiety Scale is a clinician-rated scale. Higher scores indicate more severe anxiety. Baseline (preoperative), 1 month, 3 months, 6 months, 12 months, 18 months
Secondary Changes in Hamilton Depression Scale-17 Score The Hamilton Depression Scale-17 is a clinician-rated scale. Higher scores indicate more severe depression. Baseline (preoperative), 1 month, 3 months, 6 months, 12 months, 18 months
Secondary Magnetic resonance imaging (MRI) images The MRI images contains resting, multi-tasks related, and structural states. Baseline (preoperative)
Secondary Change in memory The CANTAB software research is used to assess memory and learning. The tasks incude spatial working memory task, paired associated learning task, pattern recognition memory task. Baseline (preoperative),6 months or 12 months
Secondary Change in impulsivity and compulsivity The computerized tasks are used to measure impulsivity and compulsivity. The tasks include stop single task, beads task, model-based modle-free task and habit task. Baseline (preoperative),6 months or 12 months
Secondary Change in Young Manic Rating Scale(YMRS) The YMRS is a 11-item rating scale used to evaluate manic symptoms. Higher score indicates more severe mania. Baseline (preoperative), 1 month, 3 months, 6 months, 12 months, 18 months
Secondary Changes in SF-36 score The 36-Item Short Form Survey (SF-36) is used to measure the quality of life. The higher score means higher quality of life. Baseline (preoperative), 1 month, 3 months, 6 months, 12 months, 18 months
Secondary Changes in WHOQOL-BREF score The WHOQOL-BREF is used to measure the quality of life. The higher score means higher quality of life. Baseline (preoperative), 1 month, 3 months, 6 months, 12 months, 18 months
Secondary Changes in Q-LES-Q-SF score The quality of life enjoyment and satisfaction questionnaire - short form (Q-LES-Q-SF) is used to measure the quality of life. The higher score means higher quality of life. Baseline (preoperative), 1 month, 3 months, 6 months, 12 months, 18 months
Secondary Changes in PSQI score The pittsburgh sleep quality index (PSQI) is used to measure the quality and patterns of sleep. Higher score means poorer quality of sleep. Baseline (preoperative), 1 month, 3 months, 6 months, 12 months, 18 months
Secondary Changes in PSS-10 score The perceived stress scale (PSS-10) is used to measure stress levels and contains 10 items rated from "never" (coded as 0) to "very often" (coded as 4). Higher score means higher level of stress. Baseline (preoperative), 1 month, 3 months, 6 months, 12 months, 18 months
Secondary Changes in PANAS score The positive and negative affective schedule (PANAS) consists of 20 words that describe different feeling and emotions. 10 words constitute negative affect and positive affect subscales. Each word was rated from "very slightly or not at all" (coded as 1) to "extremely" (coded as 5). Higher score means higher level of positive or negative affect. Baseline (preoperative), 1 month, 3 months, 6 months, 12 months, 18 months
Secondary Change in Sheehan Disability Scale The Sheehan Disability Scale is a composite of three self-rated items designed to measure the extent to which three major sectors in the patient's life are impaired. The patient rates the extent to which his or her 1) work, 2) social life or leisure activities, and 3) home life or family responsibilities are impaired by his or her symptoms on a 10-point visual analog scale. Baseline (preoperative), 1 month, 3 months, 6 months, 12 months, 18 months
See also
  Status Clinical Trial Phase
Recruiting NCT04934007 - Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder N/A
Recruiting NCT04071990 - Family Involvement in CBGT of OCD: a Randomized Controlled Trial N/A
Completed NCT02541968 - Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder N/A
Recruiting NCT05651295 - A Precision Medicine Approach to Target Engagement for Emotion Regulation N/A
Recruiting NCT05391503 - Light Therapy for Obsessive-compulsive Disorder (OCD) N/A
Recruiting NCT04539951 - Pragmatic Trial of Obsessive-compulsive Disorder Phase 2
Completed NCT03416504 - Methods for Managing Intrusive Thoughts N/A
Not yet recruiting NCT06029738 - Effect on Obsessive-Compulsive Beliefs and Symptoms of MCT-OCD N/A
Recruiting NCT02844049 - European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS N/A
Terminated NCT02909660 - What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder N/A
Completed NCT02911324 - Cannabinoid Medication for Adults With OCD Phase 1/Phase 2
Completed NCT02217995 - Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients N/A
Terminated NCT02234011 - A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder Phase 2
Withdrawn NCT01953042 - Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders N/A
Completed NCT02655926 - Deep Brain Stimulation for Severe Obsessive Compulsive Disorder N/A
Completed NCT00742664 - Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project Phase 1/Phase 2
Completed NCT04919785 - Deep Brain Stimulation in Severe Obsessive-compulsive Disorder N/A
Terminated NCT00758966 - Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder Phase 2
Completed NCT00523718 - Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder Phase 2
Completed NCT00074815 - Treatment of Obsessive Compulsive Disorder in Children Phase 3